Ascendis Pharma A/S News

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

MT NewswiresDec 31 11:04 ET

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Simply Wall StDec 24, 2024 07:41 ET

Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $220

Moomoo NewsDec 20, 2024 13:31 ET · Ratings

Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults

BenzingaDec 19, 2024 08:42 ET

Jefferies Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $194

Moomoo NewsDec 18, 2024 10:31 ET · Ratings

A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $167 to $211

Moomoo NewsDec 17, 2024 08:00 ET · Ratings

Express News | Ascendis Pharma A/S : Jefferies Raises Target Price to $194 From $191

ReutersDec 17, 2024 00:11 ET

Ascendis Pharma (ASND) Gets a Buy From Stifel Nicolaus

TipRanksDec 16, 2024 21:05 ET · Ratings

Ascendis Pharma Presents New InsiGHTS Trial Of TransCon HGH In Turner Syndrome Achieved Primary Objective At Week 26; Results For All Three TransCon HGH Starting Dose Cohorts, In First Clinical Trial Of An Indication Outside Of Growth Hormone...

BenzingaDec 16, 2024 08:36 ET

Ascensis Pharma Says FDA Will Review Application for Adult Treatment of Growth Hormone Deficiency

WSJDec 12, 2024 17:21 ET

Express News | Ascendis Pharma Announces FDA Accepts Co's Supplemental Biologics License Application For TransCon HGH For The Treatment Of Adults With Growth Hormone Deficiency

BenzingaDec 12, 2024 16:02 ET

European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading

MT NewswiresDec 11, 2024 11:33 ET

Orsini Chosen by Ascendis to Distribute Treatment for Rare Endocrine Disorder in the U.S.

PR NewswireDec 9, 2024 08:00 ET

Peering Into Ascendis Pharma's Recent Short Interest

BenzingaDec 3, 2024 11:15 ET

JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG

Seeking AlphaNov 25, 2024 13:58 ET

JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas

Seeking AlphaNov 19, 2024 11:06 ET

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167

Moomoo NewsNov 19, 2024 03:36 ET · Ratings

Express News | Ascendis Pharma A/S : Citigroup Cuts Target Price to $200 From $207

ReutersNov 18, 2024 06:25 ET

A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $153 to $207

Moomoo NewsNov 16, 2024 08:00 ET · Ratings

Express News | Acendis Pharma Shares Are Trading Higher After Stifel Maintained a Buy Rating on the Stock and Raised Its Price Target From $200 to $207

BenzingaNov 15, 2024 12:08 ET